GDC 0570
Alternative Names: GDC-0570Latest Information Update: 28 Nov 2021
Price :
$50 *
At a glance
- Originator Genentech
- Class Antineoplastics; Small molecules
- Mechanism of Action PIM3 protein inhibitors; Proto oncogene protein c pim 1 inhibitors; Proto-oncogene protein pim-2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Multiple myeloma; Prostate cancer
Most Recent Events
- 28 Nov 2021 No recent reports of development identified for preclinical development in Multiple-myeloma in USA
- 28 Nov 2021 No recent reports of development identified for preclinical development in Prostate-cancer in USA
- 28 Jan 2020 GDC 0570 licensed to Ningbo NewBay Medical Technology worldwide for development and commercialisation for multiple myeloma and prostate cancer